Rhythm Pharmaceuticals/$RYTM
Rhythm Pharmaceuticals stock falls after reporting Q3 EPS of -$0.82, missing the consensus estimate of -$0.73.
13 hours agoLightyear AI
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
Ticker
$RYTM
Sector
Primary listing
Employees
283
Headquarters
Website
RYTM Metrics
BasicAdvanced
$7.6B
-
-$3.02
2.12
-
Price and volume
Market cap
$7.6B
Beta
2.12
52-week high
$116.00
52-week low
$45.91
Average daily volume
578K
Financial strength
Current ratio
2.786
Quick ratio
2.45
Long term debt to equity
82.117
Total debt to equity
85.327
Interest coverage (TTM)
-7.90%
Profitability
EBITDA (TTM)
-268.31
Gross margin (TTM)
89.25%
Net profit margin (TTM)
-117.16%
Operating margin (TTM)
-113.53%
Effective tax rate (TTM)
0.01%
Revenue per employee (TTM)
$550,000
Management effectiveness
Return on assets (TTM)
-29.39%
Return on equity (TTM)
-116.97%
Valuation
Price to revenue (TTM)
45.407
Price to book
-610.47
Price to tangible book (TTM)
-411.75
Price to free cash flow (TTM)
-65.573
Free cash flow yield (TTM)
-1.53%
Free cash flow per share (TTM)
-1.735
Growth
Revenue change (TTM)
53.55%
Earnings per share change (TTM)
-31.00%
3-year revenue growth (CAGR)
126.73%
3-year earnings per share growth (CAGR)
-4.73%
10-year earnings per share growth (CAGR)
27.01%
What the Analysts think about RYTM
Analyst ratings (Buy, Hold, Sell) for Rhythm Pharmaceuticals stock.
Bulls say / Bears say
Global net product revenue for IMCIVREE reached $48.5 million in Q2 2025, up 29% sequentially and 67% year-over-year, driven primarily by Bardet-Biedl syndrome prescriptions (GlobeNewswire).
The Phase 2 trial of oral MC4R agonist bivamelagon met its primary endpoint with statistically significant, clinically meaningful BMI reductions, validating Rhythm’s pipeline diversification beyond setmelanotide (GlobeNewswire).
In February 2025, the FDA approved an expanded IMCIVREE label to include pediatric patients aged 2 years and older, increasing the addressable market for rare genetic obesity disorders (GlobeNewswire)
The quarter’s net loss widened to $48 million, up from $33.6 million a year earlier, underscoring rising cash burn from advancing clinical programs (TipRanks).
The FDA has set a PDUFA goal date of December 20, 2025 for Rhythm’s supplemental NDA in acquired hypothalamic obesity, and any delay or negative outcome could stall expansion into a larger patient population (GlobeNewswire).
Major pharma players like Roche have committed up to $5.3 billion to develop competing obesity drugs, intensifying market competition and potentially limiting IMCIVREE’s uptake (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2025.
RYTM Financial Performance
Revenues and expenses
RYTM Earnings Performance
Company profitability
RYTM News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Rhythm Pharmaceuticals stock?
Rhythm Pharmaceuticals (RYTM) has a market cap of $7.6B as of November 05, 2025.
What is the P/E ratio for Rhythm Pharmaceuticals stock?
The price to earnings (P/E) ratio for Rhythm Pharmaceuticals (RYTM) stock is 0 as of November 05, 2025.
Does Rhythm Pharmaceuticals stock pay dividends?
No, Rhythm Pharmaceuticals (RYTM) stock does not pay dividends to its shareholders as of November 05, 2025.
When is the next Rhythm Pharmaceuticals dividend payment date?
Rhythm Pharmaceuticals (RYTM) stock does not pay dividends to its shareholders.
What is the beta indicator for Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals (RYTM) has a beta rating of 2.12. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.